Abi Vijenthira, MD, and Anca Prica, MD, on Why Certain DLBCL Therapies May Not Be Cost Effective

Drs. Vijenthira and Prica, both of the Princess Margaret Cancer Centre, speak with host Chadi Nabhan, MD, MBA, FACP, about their analysis on the cost-effectiveness of pola-R-CHP and second-line CAR-T in patients with DLBCL, and why its results differed from a similar study published in the journal Blood in December 2022.